Direxion Daily S&P Biotech Bear 3X ETF
LABD
11 hedge funds and large institutions have $13.8M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 2 closing their positions.
138% more call options, than puts
Call options by funds: $24.7M | Put options by funds: $10.4M
0.01% more ownership
Funds ownership: 0.06% → 0.08% (+0.01%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
8% less funds holding
Funds holding: 12 → 11 (-1)
13% less capital invested
Capital invested by funds: $15.8M → $13.8M (-$2.08M)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$779K |
| 2 |
Jane Street
New York
|
+$535K |
| 3 |
HF
HRT Financial
New York
|
+$350K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$320K |
| 5 |
Morgan Stanley
New York
|
+$84.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$1.9M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$952K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$392K |
| 4 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$359K |
| 5 |
Citigroup
New York
|
-$244K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $7.86M | +$84.2K | +20 | +0.9% |
|
|
BG
2
Bellevue Group
Kuesnacht,
Switzerland
| $2.02M | +$779K | +185 | +49% |
|
|
3
Jane Street
New York
| $1.32M | +$535K | +127 | +53% |
|
|
4
Simplex Trading
Chicago,
Illinois
| $641K | +$320K | +76 | +75% |
|
|
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $587K | -$952K | -226 | -58% |
|
6
Citadel Advisors
Miami,
Florida
| $566K | -$236K | -56 | -26% |
|
|
HF
7
HRT Financial
New York
| $298K | +$350K | +83 | New |
|
|
VF
8
Virtu Financial
New York
| $232K | -$1.9M | -451 | -88% |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| $118K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $81K | -$392K | -93 | -81% |
|
11
UBS Group
Zurich,
Switzerland
| $29K | – | – | – |
|
|
MMA
12
Miracle Mile Advisors
Los Angeles,
California
| – | -$359K | -98 | Closed |
|
|
13
Citigroup
New York
| – | -$244K | -58 | Closed |
|
LABD Hedge Fund Activity: Q2 2019 in Review
11 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q2 2019, worth a combined $13.8M — down 13% from $15.8M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LABD and 1 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Bellevue Group, adding an estimated $779K. The largest seller was Virtu Financial, cutting an estimated $1.9M.
- 11 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q2 2019, down from 12 in Q1 2019.
- Funds reported $13.8M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q2 2019, down 13% quarter-over-quarter.
- 1 fund opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q2 2019 was Bellevue Group, an estimated $779K added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q2 2019 was Virtu Financial, an estimated $1.9M sold.
Based on aggregated 13F filings for Q2 2019.